New Development in Weight Loss Medication
Scientists in Sweden are working on an innovative pill aimed at enhancing fat burning and regulating blood sugar levels in a manner distinct from well-known GLP-1 medications like Ozempic.
Unlike the injectable GLP-1 treatments that reduce appetite, this new oral option encourages muscle metabolism instead.
The research, led by teams from Karolinska Institutet and Stockholm University, included early animal experiments alongside human clinical trials involving 48 healthy adults and 25 individuals with type 2 diabetes.
The oral drug has shown promise in managing blood sugar, boosting fat burning, and maintaining muscle mass in animal studies, and it was found to be very well tolerated in humans.
Researchers pointed out that this new medication also has fewer side effects compared to existing GLP-1 treatments like semaglutide and tirzepatide, which are notorious for causing decreased appetite, gastrointestinal issues, and muscle deterioration.
This experimental drug introduces a different kind of beta-2 agonist that supports muscle health while sidestepping potential heart-related problems associated with older versions.
The results of this study were published in the journal Cell this week.
There’s potential for this new pill to be used independently or alongside GLP-1 medications, according to the researchers.
Professor Torre Bengtsson from the Department of Molecular Biosciences at Stockholm’s Wenner Gren Institute expressed optimism, stating, “Our results point to the future of improving metabolic health without losing muscle mass.” He highlighted the crucial role of muscle in both type 2 diabetes and obesity, noting that muscle mass is linked to longevity.
Shane C. Wright, an assistant professor at Karolinska Institutet, emphasized the drug’s possible significance for those struggling with type 2 diabetes and obesity, mentioning that this treatment promotes healthy weight loss without the need for injections.
Dr. Trey Wickham, who is the interim chief of Endocrinology, Diabetes, and Metabolism at VCU Health in Richmond, Virginia, acknowledged the potential impact of this compound. He noted that “this compound’s mechanism of action has the potential to address certain metabolic issues in traditional weight loss therapies, such as the loss of both muscle and adipose tissue.” However, he also cautioned that “while the preliminary results are intriguing, thorough testing in larger, longer-term studies is essential to ensure safety and understand how this compound can contribute to comprehensive obesity and diabetes treatments.”
Researchers recognized limitations in their study, particularly that animal models may not fully reflect the complexities of these conditions in humans. They stressed the need for structural studies to grasp how the drug functions.
Looking ahead, Atrogi AB, the company behind the drug, plans to initiate a larger Phase 2 clinical trial involving a more diverse group of participants, including those who are obese.
